In ovarian carcinoma, BCL-XL and MCL1 are gateway proteins guarding together against apoptosis and their concomitant inhibition is sufficient to elicit apoptosis in chemoresistant ovarian cancer cell lines.7, 8, 9 On the basis of this assumption, the development of therapeutic strategies aiming at targeting concomitantly these two proteins could constitute an interesting alternative treatment of ovarian carcinoma. Here, BCL2L1 is linked to ovarian carcinoma.